← 返回

IFNα和 5-Aza-2'-脱氧胞苷联合靶向树突状细胞的 DNA 疫苗改变 B16F10 黑色素瘤模型中的肿瘤免疫细胞浸润

英文原题:IFNα and 5-Aza-2'-deoxycytidine combined with a dendritic-cell targeting DNA vaccine alter tumor immune cell infiltration in the B16F10 melanoma model.

查看英文原题

IFNα and 5-Aza-2'-deoxycytidine combined with a dendritic-cell targeting DNA vaccine alter tumor immune cell infiltration in the B16F10 melanoma model.

PubMed 2023/01/19(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

利用趋化因子融合疫苗高效地将抗原靶向未成熟 DC,为经典疫苗和基于 DC 的疫苗提供了一种潜在的替代方法。将该方法与 IFNα和 5Aza 治疗联合使用可显著提高疫苗效力。这种治疗创造了一个炎症趋化因子增加的环境,有利于 CD8+ DC、NK 细胞和 CD8+ T 细胞(尤其是记忆细胞)的迁移,同时减少 MDSCs 的数量。重要的是,在联合治疗组中,CD8+细胞不仅数量更多,而且更能穿透肿瘤组织。进一步分析我们联合治疗所涉及的信号通路,有望为黑色素瘤发病机制提供更多见解,并促进新型治疗策略的开发。

研究思路结论见上方概要

含有编码趋化因子 MIP-3α(CCL20)基因与黑色素瘤相关抗原基因融合的 DNA 疫苗,其中 MIP-3α 是未成熟树突状细胞(DCs)上 CCR6 的配体,与不含趋化因子基因的疫苗相比,具有增强的抗肿瘤免疫和疗效。先前的研究表明,I 型干扰素(IFNα 或 IFN)和 5-Aza-2'-脱氧胞苷(5Aza)显著增强了 DNA 疫苗的治疗效果,表现为肿瘤负荷减少和小鼠生存期改善。

在此,我们探索了该联合方案(疫苗、IFN和5Aza)相较于单独疫苗以及无疫苗的IFN和5Aza的治疗获益背后的小鼠肿瘤内免疫相关性,重点通过qRT-PCR检测趋化因子mRNA表达,并通过流式细胞术和IHC检测肿瘤微环境(TME)中的炎症细胞浸润。

联合治疗组显著上调了肿瘤内关键免疫浸润趋化因子XCL1和CXCL10的mRNA表达。肿瘤悬液的流式细胞术分析显示,联合治疗组中CD8+ DCs、CCR7+ DCs和NK细胞的肿瘤浸润增加,而接种疫苗组中髓源性抑制细胞(MDSCs)水平降低。接受联合治疗的小鼠还具有更高比例的效应/记忆T细胞(Tem),此外还显示出Tem和中枢记忆CD8+ T细胞(Tcm)浸润增强。Tem和Tcm群体均与较小的肿瘤尺寸相关。肿瘤的免疫组化分析证实,联合治疗中CD8+细胞总体更为丰富,尤其是在肿瘤实质中。

展开英文摘要原文

Here, we explored mouse intratumoral immune correlates underlying the therapeutic benefit of this combination regimen (vaccine, IFN, and 5Aza) as compared to vaccine alone and IFN and 5Aza without vaccine, focusing on chemokine mRNA expression by qRT-PCR and inflammatory cellular infiltration into the tumor microenvironment (TME) by flow cytometry and immunohistochemistry (IHC).

The combination group significantly upregulated intratumoral mRNA expression of key immune infiltration chemokines XCL1 and CXCL10. Flow cytometric analyses of tumor suspensions exhibited greater tumor infiltration of CD8+ DCs, CCR7+ DCs, and NK cells in the combination group, as well as reduced levels of myeloid-derived suppressor cells (MDSCs) in vaccinated groups. The mice receiving combination therapy also had greater proportions of effector/memory T-cells (Tem), in addition to showing an enhanced infiltration of Tem and central memory CD8+ T-cells, (Tcm). Tem and Tcm populations both correlated with smaller tumor size. Immunohistochemical analysis of tumors confirmed that CD8+ cells were more abundant overall and especially in the tumor parenchyma with combination therapy. DISCUSSION: Efficient targeting of antigen to immature DCs with a chemokine-fusion vaccine offers a potential alternative approach to classic and dendritic cell-based vaccines. Combining this approach with IFNα and 5Aza treatments significantly improved vaccine efficacy. This treatment creates an environment of increased inflammatory chemokines that facilitates the trafficking of CD8+ DCs, NK cells, and CD8+ T-cells, especially memory cells, while reducing the number of MDSCs. Importantly, in the combination group, CD8+ cells were more able to penetrate the tumor mass in addition to being more numerous. Further analysis of the pathways engaged by our combination therapy is expected to provide additional insights into melanoma pathogenesis and facilitate the development of novel treatment strategies.

论文信息

作者
Gordy JT、Sandhu AK、Fessler K、Luo K、Kapoor AR、Ayeh SK、Hui Y、Schill C
单位
Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.United States
文献类型
美国 NIH 资助研究 · 非美国政府资助研究
期刊
Frontiers in immunology2022
原文标识
PubMed 36741387 · DOI 10.3389/fimmu.2022.1074644